A global product development and go-to-market strategy are essential for any pharma company looking to globalize. While it is natural that China biotech companies apply for market approval in China first followed by the US and other markets, the initial regulatory and medical considerations for these products are not always fully aligned with a strategy of seeking approval outside of the region.
By examining case studies of drugs produced in China, but which faced regulatory hurdles in the US, Syneos Health experts examine how working with the right partners for drug discovery, regulatory strategy, clinical studies, manufacturing and product distribution is the foundation for any successful global product development strategy.
Download the white paper below
